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SYNOPSIS 
Lafora progressive myoclonus epilepsy (Lafora disease; LD) is a fatal autosomal 
recessive neurodegenerative disorder caused by loss-of-function mutations in either the 
EPM2A gene, encoding the dual specificity phosphatase laforin, or the EPM2B gene, 
encoding the E3-ubiquitin ligase malin. Previously, we and others showed that laforin 
and malin form a functional complex that regulates multiple aspects of glycogen 
metabolism, and that the interaction between laforin and malin is enhanced by 
conditions activating AMP-activated protein kinase (AMPK). Here, we demonstrate that 
laforin is a phosphoprotein, as indicated by two-dimensional electrophoresis, and we 
identify Ser25 as the residue involved in this modification. We also show that Ser25 is 
phosphorylated both in vitro and in vivo by AMPK. Lastly, we demonstrate that this 
residue plays a critical role for both the phosphatase activity and the ability of laforin to 
interact with itself and with previously established binding partners. Our data suggest 
that phosphorylation of laforin-Ser25 by AMPK provides a mechanism to modulate the 
interaction between laforin and malin. Regulation of this complex is necessary to 
maintain normal glycogen metabolism. Importantly, Ser25 is mutated in some Lafora 
disease patients (S25P), and our results begin to elucidate the mechanism of disease in 
these patients. 
 
Abbreviations: CBD, carbohydrate binding domain; 2DE, two-dimensional 
electrophoresis; DSPD, dual specificity phosphatase domain; DTT, dithiothreitol; GFP, 
green fluorescent protein; OMFP, 3-O-methyl fluorescein phosphate; PDB, protein data 
bank; VHR, vaccinia H1-related phosphatase 
 
 
INTRODUCTION 
Lafora progressive myoclonus epilepsy (LD, OMIM 254780) is a fatal autosomal 
recessive neurodegenerative disorder characterized by the presence of progressive 
neurological deterioration, myoclonus and epilepsy (see [1] and [2] for review). LD 
initially manifests during adolescence with generalized tonic-clonic seizures, 
myoclonus, absences, drop attacks and visual hallucinations. As the disease proceeds, 
patients enter into a vegetative state and eventually die, usually within the first decade 
from onset of the first symptoms ([1], [3]). Mutations causing LD have been identified 
in two genes, EPM2A ([4], [5]) and EPM2B (NHLRC1) [6], and there is evidence for a 
third locus [7]. 
EPM2A encodes laforin, a dual specificity phosphatase with a functional 
carbohydrate binding domain at the N-terminus ([8], [9]). EPM2B encodes malin, an 
E3-ubiquitin ligase with a RING finger domain at the N-terminus and six NHL domains 
involved in protein-protein interactions in the C-terminal region ([6], [10], [11]). A 
hallmark of LD is the accumulation of insoluble glucans (i.e. carbohydrates) called 
Lafora bodies (LBs) ([12], [13]). LBs form in the cytoplasm of cells from most tissues. 
LBs, like normal glycogen, are composed of glucose residues joined by -1,4-
glycosidic linkages with branches occurring via -1,6-glycosidic linkages (reviewed in 
[2]). However, the branches are less frequent in LBs compared to glycogen, making 
LBs water insoluble. It has been recently described that laforin directly interacts with 
malin, forming a laforin-malin complex, and that laforin recruits specific substrates to 
be ubiquitinated by malin ([10], [11], [14]). Given the reoccurring theme of glycogen 
and carbohydrates in LD, it is not surprising that some substrates of the laforin-malin 
complex are integrally involved in regulating glycogen biosynthesis. The laforin-malin 
complex ubiquitinates the muscle isoform of glycogen synthase (MGS) [15], the 
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glycogen debranching enzyme (GDE/AGL) [16], and the glycogen targeting subunit of 
type 1 protein phosphatase (PP1) called protein targeting to glycogen (R5/PTG) ([14], 
[17]). While multiple groups have corroborated these findings, there is dissent 
concerning they are in vivo substrates of the malin-laforin complex ([18], [19]). 
Despite these important genetic findings, the physiological roles of laforin and 
malin are only beginning to be understood and it is still unclear which cellular 
processes, altered by the absence of these proteins, give rise to the devastating disorder 
of LD. More recently, an alternative function for laforin in glycogen homeostasis has 
been described ([20], [21], [22]). In this case, laforin acts as a phosphatase of glycogen 
and it has been proposed that this function might be necessary for the maintenance of 
normal cellular glycogen ([20], [22], [23]). 
We have recently demonstrated that the activity of the laforin-malin complex is 
modulated by the AMP-activated protein kinase (AMPK), but no modified residue was 
identified and the mechanism driving this modulation is currently unknown [14]. 
However, it is clear that activated AMPK increases the interaction between laforin and 
malin, and the increased interaction enhances the degradation of R5/PTG by the laforin-
malin complex [14]. The degradation of R5/PTG inhibits the glycogenic activity of 
R5/PTG and down-regulates glycogen production. Cumulatively, these results highlight 
the importance of the laforin-malin complex in regulating glycogen biosynthesis, and 
these molecular events are consistent with the accumulation of the glycogen-like 
intracellular LBs. However, despite these findings, it is currently unclear whether the 
accumulation of Lafora bodies is the cause of the disease or is a secondary determinant 
of a primarily established metabolic alteration. 
As mentioned above, laforin is a dual specificity phosphatase and as such 
contains a DSP domain (DSPD) at the C-terminus. Accordingly, recombinant laforin is 
able to dephosphorylate in vitro artificial substrates such as p-nitrophenylphosphate and 
3-O-methyl fluorescein phosphate (OMFP; a more sensitive substrate of dual specificity 
phosphatases) ([24], [25], [26]). In addition to the capacity of laforin to dephosphorylate 
glycogen (see above), it has been suggested that laforin dephosphorylates proteinaceous 
substrates such as glycogen synthase kinase 3 (GSK3) ([27], [28]), although this is a 
controversial issue ([20], [21]). 
In this work, we present evidence that laforin is a phosphoprotein that is 
phosphorylated at residue Ser25 by AMPK. In addition, we demonstrate that this 
residue plays critical roles in laforin function, affecting phosphatase activity and the 
ability of laforin to interact with itself and with previously established binding partners. 
Since Ser25 is mutated in some Lafora disease patients (S25P), our results begin to 
elucidate the mechanism of disease in this population of patients. 
 
 
EXPERIMENTAL 
Cell models, culture conditions and genetic methods. 
Escherichia coli DH5 was used as the host strain for plasmid constructions. E. coli 
BL21 (RIL) was used for protein production. They were grown in LB (1% peptone, 
0.5% yeast extract, 1% NaCl, pH 7.5) medium supplemented with 50 mg/L ampicillin. 
Yeast strains used in this work were FY250 (MAT his3200 leu21 trp163 ura3-52) 
and CTY10-5d (MATa ade2 his3 leu2 trp1 gal4 gal80 URA3::lexAop-lacZ; gift from R. 
Sternglanz, State University of New York, Stony Brook, USA). Yeast transformation 
was carried out using the lithium acetate protocol [29]. Yeast cultures were grown in 
synthetic complete (SC) medium lacking the corresponding supplements to maintain 
selection for plasmids [30]. 
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Human embryonic kidney (HEK293) cells, hamster ovary (CHO) cells and 
control and double AMPK12 KO mouse embryonic fibroblasts (MEFs, kindly 
provided by Dr. Benoit Viollet, Institut Cochin, Université Paris Descartes, Paris, 
France) were grown in DMEM (Lonza) supplemented with 100 units/ml penicillin, 100 
μg/ml streptomycin, 2 mM glutamine, 10% inactivated fetal bovine serum (FBS, 
GIBCO). 1.5x106 cells were plated onto 60mm-diameter culture dishes the day before 
transfection. Cells were transfected with 1 μg of each plasmid using Lipofectamine 
2000 (Invitrogen). In [32P]-orthophosphate labelling experiments, we grew cells to sub-
confluency, transfected the cells and twenty four hours later the cells were washed with 
phosphate-free DMEM. Then, cells were then incubated in DMEM-free media for 0.5 
hours, 0.25mCi/ml [32P]-orthophosphate and 10M MG132 were added, the cells were 
incubated for 5 hours, and denatured immunoprecipitations were preformed as 
previously described [11]. 
 
Plasmids 
Plasmids pEG202-laforin S25A, T45A, T83A, S98A, T111A, T133A, T136A, T142A, 
T143A, S158A, S168A, T177A, T187A, T194I, S202/3A, T213A, T216A, T233A, 
S237/T238A, S273/T274A, S326A, S327A and S330A, were obtained by site directed 
mutagenesis using plasmid pEG202-laforin [14] as template, the Quick Change kit 
(Stratagene) and the corresponding mutagenic oligonucleotides. These mutagenic 
nucleotides contained the corresponding 21 nucleotides upstream the codon to be 
mutagenized and the downstream 21 nucleotides (45 nucleotides in total), based on the 
human laforin cDNA. Nucleotides in the mutated codon were replaced by the 
appropriated nucleotides to code for Ala (only in the case of T194I, nucleotides were 
changed to code for Ile). Similarly we constructed plasmids pEG202-laforin S25D, 
S168D, T187D and T194D. In this case nucleotides in the mutated codon were changed 
to code for Asp. The sequences of all these mutagenic oligonucleotides are available 
upon request. All mutants were sequenced to ensure that additional mutations were not 
introduced during the mutagenesis procedure. Plasmids pACT2-laforin WT, S25A, 
S25D and T194I were obtained by digesting the corresponding pEG202-laforin 
plasmids with BamHI and SalI and cloning the corresponding fragment into pACT2, 
digested with the same set of restriction enzymes. 
 Plasmids pCMVmyc-laforin WT, S25A, S25D and T194I were obtained by 
digesting the corresponding pACT2-laforin plasmids with SfiI and BglII and subcloning 
the corresponding fragment into pCMVmyc (BD Biosciences), digested with the same 
set of restriction enzymes. Plasmids pWSGST-laforin WT, S25A and S25D were 
obtained by digesting the corresponding pEG202-laforin plasmids with BamHI/SalI and 
subcloning the fragments into the pWSGST vector [31]. 
Other plasmids used in this study were: pACT2-malin, pACT2-R5/PTG, 
pACT2-AMPK2 [14]. Plasmid pGEX4T1-VHR was a generous gift of Dr. Rafael 
Pulido (Centro de Investigacion Principe Felipe, Valencia, Spain). Plasmid pEGFP-N1 
was from BD-Biosciences. pEGB2 AMPK1 wild type, -kinase dead (KD, AMPK1 
D157A), and -constitutively active (CA, AMPK1 residues 1-312) were kind gifts from 
Dr. Reuben Shaw (Salk Institute, San Diego, USA) [32]. 
 
Yeast two hybrid analyses. 
Yeast CTY10.5d strain was co-transformed with combinations of pACT2-malin, 
pACT2-R5/PTG and pACT2-AMPK2 and different pEG202-laforin mutant plasmids. 
Transformants were grown in selective SC medium (4% glucose) and shifted to low 
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glucose conditions (0.05% glucose) for 3 hours when indicated. Then, -galactosidase 
activity was assayed in permeabilized cells and expressed in Miller Units as in [33].  
 
Expression of recombinant proteins. 
E.coli transformants harboring the pGEX4T1-VHR plasmid were grown in 500 ml of 
LB/ampicillin. Transformants were grown at 37ºC until the absorbance at 600 nm 
reached a value of around 0.3. IPTG was then added to a final concentration of 0.1 mM, 
and cultures were maintained overnight at 25 ºC. Cells were harvested and resuspended 
in 20 ml of sonication buffer 50 mM HEPES-NaOH pH 7.0, 150 mM NaCl, 10% 
glycerol, 0.1% Triton X-100, 2 mM DTT, 2 mM PMSF and complete protease inhibitor 
cocktail (Roche)]. Cells were disrupted by sonication and the fusion proteins purified by 
passing the extracts through columns containing 1 ml bed volume of glutathione-
sepharose (GE Healthcare). GST-fusion proteins were eluted from the column with 50 
mM glutathione. Samples were stored at -80ºC. 
FY250 yeast cells were transformed with plasmids pWSGST-laforin WT, S25A 
and S25D. Yeast extracts were prepared as described in [34]. Extraction buffer was 50 
mM Tris/HCl (pH 7.5), 150 mM NaCl, 0.1% Triton X-100, 1 mM dithiothreitol and 
10% glycerol, and contained 2 mM PMSF and a complete protease inhibitor cocktail 
(Roche). GST-fusion proteins were purified and eluted as described above. 
 
Immunodetection. 
HEK293 cells were transfected with the corresponding plasmids. Twenty-four hours 
after transfection, cells were scraped on ice in lysis buffer [10 mM TrisHCl pH 8; 150 
mM NaCl, 15 mM EDTA; 0.6 M sucrose, 0.5% nonidet P-40 (NP-40), complete 
protease inhibitor cocktail (Roche), 1 mM PMSF, 50 mM NaF and 5 mM Na2P2O7]. 
Cells were lysed by repeated passage through a 25-gauge needle. Twenty-five g of 
total protein from the soluble fraction of cell lysates were analyzed by SDS-PAGE and 
western blotting using appropriate antibodies: anti-myc, anti-tubulin (Sigma) and anti-
GFP (Immunokontact). Yeast extracts were prepared as described previously [34]; 
samples (15 g) were separated by SDS-PAGE and analyzed by western blotting using 
the corresponding anti-LexA (Santa Cruz Biotechnology), anti-HA (Sigma) and anti-
GST (GE Healthcare) antibodies. 
 
Non-denaturing gel electrophoresis 
Cell extracts were freshly prepared in SDS- and DTT-free loading buffer (125 mM Tris-
HCl, 20% Glycerol), samples were not heated, and then analysed by regular SDS-PAGE 
and western blotting.  
 
2D-electrophoresis.  
Mammalian HEK293 cells were transfected with pCMVmyc-laforin (wild type, S25D 
and T194I) plasmids and 24 hours after transfection, extracts were prepared in urea lysis 
buffer (9.7 M urea, 4% CHAPS, 20 mM DTT). Myc-laforin derivatives were analyzed 
by two-dimensional electrophoresis (2DE) using an IPGphor (Amersham Bioscience) 
instrument. For the first dimension (IEF), 50 μg of total protein (in 100 μl of 9.7 M urea, 
4% CHAPS, 20 mM DTT and 0.5 % IPG buffer) were loaded on a 7 cm IPG strip (pH 
range 4-7) using the following focusing conditions: 500 V for 30 min, 1000 V for 30 
min and 5000 V for 80 min. Electrophoretic separation (second dimension) was 
performed using SDS-PAGE. When indicated, extracts were also prepared in -
phosphatase buffer containing 2 mM MnCl2. Fifty micrograms of crude extract was 
treated at 30ºC for 30 min with 50 Units of -phosphatase (New England Biolabs). 
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Reactions were stopped by adding two volumes of urea lysis buffer and analyzed by 2-
D electrophoresis as above. The same protocol was used to analyze mouse embryonic 
fibroblasts transfected with pCMVmyc-laforin. 
 
In vitro kinase assays.  
Kinase assays were performed with 5.0 ng of recombinant AMPK (Sigma) incubated 
with 100 ng of recombinant non-tagged human laforin (Hs-laforin-NT) in kinase buffer 
(25 mM MOPS, pH 7.2, 12.5 mM glycerol, 25 mM MgCl2, 5 mM EDTA, 2 mM EGTA, 
and 0.25 mM DTT) along with 0.5 mM AMP and 1 Ci of [-32P]ATP (Perkin Elmer). 
After 15 minutes at 30˚C, SDS-PAGE buffer was added to each sample at 4˚C to stop 
the reaction. Samples were separated by SDS-PAGE, followed by transfer to PVDF, 
and autoradiography.  
 
Identification of phosphorylation sites. 
In vitro kinase assays were performed as above in the absence of [-32P]ATP. After 
purification of Hs-laforin by affinity chromatography, SDS-PAGE, and Coomassie blue 
staining, bands corresponding to Hs-laforin were excised from the gel. The gel slices 
were reduced with dithiothreitol and alkylated with iodoacetamide. Following in-gel 
trypsin and chymotrypsin digestion, the peptides were analyzed by automated 
microcaplillary liquid chromatography-tandem mass spectrometry. Fused-silica 
capillaries (100 m i.d.) were pulled using a P-2000 CO2 laser puller (Sutter 
Instruments, Novato, CA) to a 5 m i.d. tip and packed with 10 cm of 5 m Magic C18 
material (Agilent, Santa Clara, CA) using a pressure bomb. This column was then 
placed in-line with a Dionex 3000 HPLC equipped with an autosampler. The column 
was equilibrated in buffer A, and the peptide mixture was loaded onto the column using 
the autosampler. The HPLC separation at a flow rate of 300 nl/min was provided by a 
gradient between Buffer A and Buffer B (98% acetonitrile, 0.1% formic acid). The 
HPLC gradient was held constant at 100% buffer A for 5 min after peptide loading 
followed by a 30-min gradient from 5% buffer B to 40% buffer B. Then, the gradient 
was switched from 40% to 80% buffer B over 5 min and held constant for 3 min. 
Finally, the gradient was changed from 80% buffer B to 100% buffer A over 1 min, and 
then held constant at 100% buffer A for 15 more minutes. The application of a 1.8 kV 
distal voltage electrosprayed the eluted peptides directly into a Thermo LTQ ion trap 
mass spectrometer equipped with a custom nanoLC electrospray ionization source. Full 
masses (MS) spectra were recorded on the peptides over a 400-2000 m/z range, 
followed by five tandem mass (MS/MS) events sequentially generated in a data-
dependent manner on the first, second, third, fourth and fifth most intense ions selected 
from the full MS spectrum (at 35% collision energy). Mass spectrometer scan functions 
and HPLC solvent gradients were controlled by the Xcalibur data system 
(ThermoFinnigan, San Jose, CA). MS/MS spectra were extracted from the RAW file 
with ReAdW.exe (http://sourceforge.net/projects/sashimi). The resulting mzXML file 
contains all the data for all MS/MS spectra and can be read by the subsequent analysis 
software. The MS/MS data was searched with Inspect [35] against a database containing 
laforin in addition to an E.coli database plus common contaminants, with modifications: 
+16 on Methionine, +57 on Cysteine, +80 on Serine, Threonine, and Tyrosine. Only 
peptides with at least a p-value of 0.01 were analyzed further. Phosphorylated peptides 
were manually verified. 
 
Carbohydrate binding assay. 
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Crude extracts from yeast cell cultures (400 ml) expressing GST-laforin (WT, S25A and 
S25D) were obtained as above. Extracts (5 ml) were passed through columns containing 
150 l bed volume of amylose-sepharose (GE Healthcare). Flow-through was collected 
and columns were washed twice with 5 ml of extraction buffer, collecting the second 
wash volume. Bound proteins were eluted with 50 l of SDS-PAGE sample buffer. 
Collected samples (30 l) were analysed by SDS-PAGE and western blotting using 
anti-GST (GE Healthcare) antibodies. 
 
Phosphatase activity 
In vitro phosphatase assays were performed using 4 μg of GST-fusion proteins diluted 
in phosphatase buffer (0.1 M Tris-HCl, 40 mM NaCl, 10 mM DTT), in the presence of 
0.5 mM 3-O-methyl fluorescein phosphate (OMFP, Sigma). Reactions were carried out 
at 37º C in a final volume of 200 μl in 96-well ELISA plates. Phosphatase activity was 
measured for 3 hours as absorbance at 490 nm. One Unit of phosphatase activity is 
defined as the one unit of change in the absorbance at 490 nm per min of assay. 
 
Molecular modeling 
HHpred search [36] and InterPro domain scan [37] were used to determine the best 
available template for modeling the CBD and DSP of laforin. The top three hits from 
each were aligned with the CBD of laforin using PROfile Multiple Alignment with 
predicted Local Structure 3D (PROMALS) [38]. A homology model for the CBD of 
laforin was generated using the ESyPred3D server [39] with the PDB file 1CYG 
(Geobacillus stearothermophilus cyclodextrin glycosyltransferase; 29 % identity) as the 
template. Similarly, the PDB file 1WRM (Homo sapiens DUSP22 phosphatase; 13.2 % 
identity) was used to generate a homology model for the laforin DSP domain. 
Cyclodextrin moieties were docked after superimposition of laforin CBD structural 
model with the Aspergillus niger glucoamylase CBD structure (PDB: 1AC0). Images 
were generated with PyMOL (http://www.pymol.org). 
 
Statistical analyses. 
Values are given as means ± SD of at least three independent experiments. When 
indicated, differences between groups were analyzed by two-tailed student’s t-tests. The 
significance has been considered at * p<0.05 and ** p<0.01, as indicated in each case. 
 
 
RESULTS 
Mutation of Ser/Thr residues to Ala influences the interaction of laforin with malin 
and with other established binding partners. 
We and others have described that laforin interacts physically with malin ([10], [11], 
[14]). We have also recently described that the interaction between laforin and malin is 
enhanced by conditions that activate AMP-activated protein kinase (AMPK, a sensor of 
energy status), such as low glucose conditions. In addition, we demonstrated that laforin 
but not malin directly interacted with different subunits of the AMPK complex [14]. To 
test whether phosphorylation of laforin is responsible for the enhanced interaction 
between laforin and malin, we substituted each of the 26 Ser/Thr residues present in 
laforin with Ala residues and analyzed by yeast two-hybrid the strength of the laforin-
malin interaction. As reported previously, the two-hybrid interaction between wild type 
laforin and malin increased under low glucose conditions (Fig. 1A), possibly because of 
the action of activated endogenous SNF1 complex (the yeast AMPK orthologue) [14]. 
We then analyzed the interaction between mutated laforin and malin and noticed that 
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some Ser/Thr to Ala substitutions did not greatly affect the glucose regulated interaction 
between laforin and malin, whereas others improved the interaction between these two 
proteins under conditions of low glucose (i.e. T45A, T83A, T136A, S327A, etc.). 
However, only four mutations abolished the interaction between laforin and malin, in 
both high and low glucose conditions, namely S25A, S168A, T187A and T194I (in the 
latter case, the Thr residue was substituted by Ile to mimic a mutation recovered from 
Lafora patients [40]). Western blot analyses confirmed that all the mutated forms were 
expressed at similar levels (not shown). 
 We reasoned that if the phosphorylation of one of these residues was responsible 
for the enhanced interaction between laforin and malin under low glucose conditions, 
then, substitution of this residue to the phosphomimetic residue Asp should recover the 
interaction between laforin and malin. Thus, we constructed the corresponding Ser/Thr 
to Asp mutants and observed that in the case of the S168D and T187D mutants the 
interaction with malin was still impaired, suggesting that these two residues may play 
important roles in the conformation of the protein and changes to either Ala or Asp 
could severely affect the overall structure of the protein. Alternatively, in the case of 
S25D and T194D the interaction with malin was recovered, although this recovery was 
lower in the T194I mutant (Fig. 1B; western blot analyses confirmed that the mutated 
forms were expressed at similar levels as wild type). In the case of S25D mutant, the 
interaction with malin under low glucose conditions was larger than in wild type, 
suggesting that a negative charge on this residue allowed a better regulation of the 
interaction between laforin and malin by glucose. 
In addition to interacting with malin, we have also described that laforin 
interacts with the PP1 regulatory subunit R5/PTG and with subunits of the AMPK 
complex [14]. Therefore, we investigated if mutations in Ser25 and Thr194 affected the 
interaction with these partners. We observed that the S25A and T194I mutants did not 
interact with either R5/PTG or AMPK2, whereas the S25D and T194D forms allowed 
the interaction with these components (Fig. 1C; western blot analyses confirmed that the 
mutated forms were expressed at similar levels as wild type). 
 
Laforin is a phosphoprotein and is phosphorylated on residue Ser25. 
The results described above indicated that the substitution of Ser/Thr residues (S25, 
T194) by non-phosphorylatable residues (Ala and Ile, respectively), prevented the 
interaction of laforin with different binding partners. These results suggested that either 
the presence of a polar amino acid (Ser/Thr) or the phosphorylation of these residues 
could be essential for the interaction of laforin with its corresponding partners. To 
discern between the two, we expressed the mutated forms in mammalian cells 
(HEK293) and analyzed their in vivo phosphorylation status by two-dimensional 
electrophoresis (2DE). As shown in Fig. 2A (upper left panel), wild type laforin 
migrates as two major species on the 2DE gels, indicative of phosphoprotein species. 
Furthermore, treatment of the sample with -phosphatase eliminated the spot that 
moved faster towards the positive pole (right spot), suggesting that this form is due to 
phosphorylation (Fig. 2A, upper right panel). The isoelectric point of the left spot was in 
agreement with the calculated pI for the myc-laforin fusion protein (pI: 6.15) and the 
isoelectric point of the right spot (pI: 6.00) was compatible with the acquisition of one 
phosphate group. 
We attempted to analyze the phosphorylation pattern of a laforin-S25A mutant 
but the steady state levels of this protein were greatly diminished (Fig. 2B). Co-
transfection experiments using a plasmid expressing GFP under the same promoter as 
the laforin constructs indicated that the low levels of the laforin-S25A protein were not 
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due to different transfection efficiency, since similar levels of GFP were observed in 
cells co-transfected with laforin or laforin-S25A constructs. In addition, laforin-S25A 
was not in the pellet after a high speed spin, indicating that it did not form insoluble 
aggregates (Fig. 2B). These results indicate that the stability of the laforin-S25A form 
could be greatly reduced, likely due to enhanced proteolytic turnover. In agreement with 
this proposal we observed an accumulation of laforin-S25A protein when the cells were 
treated with the proteasome inhibitor MG132 (Fig. 2C). Therefore, although we cannot 
discard the possibility that the S25A mutation could affect the stability of the 
corresponding mRNA when expressed in mammalian cells, our results suggest that the 
laforin-S25A form is very unstable and gets rapidly degraded by the cellular proteolytic 
system. The reduced levels of laforin-S25A were only observed when the constructs 
were expressed in mammalian cells, but not when they were expressed in yeast (see Fig. 
1). 
Since laforin-S25D was expressed in mammalian cells (although at lower levels 
than wild type), we used this form in the 2DE experiments. We observed that laforin-
S25D migrated as a single spot and treatment of the extracts with -phosphatase did not 
produce any shift in its mobility, indicating that this form was not phosphorylated in 
vivo (Fig. 2A, middle panel). Due to the negative charge of the new Asp residue, this 
form migrated between pI 6.15 and 6.0. Conversely, laforin-T194I showed the presence 
of two major spots that migrated at similar isoelectric points as those that we observed 
for wild type laforin (Fig. 2A, lower panel) (the observed doublet in each spot could be 
due to partial degradation of the sample). 
Cumulatively, these results indicate that laforin is a phosphoprotein in vivo and 
that Ser25 is the residue that is phosphorylated. The lack of interaction between laforin-
S25A with malin, R5/PTG and AMPK is likely due to either the absence of Ser25 
phosphorylation or most likely to an altered conformation of laforin-S25A mutant. On 
the contrary, the decreased interaction of laforin-T194I with these proteins is likely due 
to a conformational change due to the presence of a non-polar Ile194 residue and not to 
a lack of phosphorylation of this mutant. 
 
Mutation of Ser25 to either Ala or Asp maintains binding to carbohydrates but 
reduces phosphatase activity. 
Since no crystal structure of laforin is yet available and in order to map the position of 
the Ser25 residue in the laforin molecule, we modelled the structure of the carbohydrate 
binding domain of laforin (residues 1-116) (Fig. 3A and 3B). We first searched the 
published CBD crystal structures to identify the best template for homology modelling. 
We identified the Geobacillus stearothermophilus cyclodextrin glycosyltransferase 
(PDB: 1CYG) as having the maximum identity with laforin (29%) and generated a 
homology model using 1CYG as the template. The homology model suggests that the 
laforin CBD folds into the characteristic two -sheets fold, each consisting of three to 
six antiparallel -strands and with the N- and C-termini pointing towards opposite ends 
of the longest axis of the molecule (Fig. 3A and 3B) [41]. Conserved aromatic residues 
involved in carbohydrate binding were readily observable in the laforin CBD structure: 
W32, W85 and W99. In the model, these residues form a compact, rigid and surface-
exposed hydrophobic site containing inter-ring spacing appropriate for binding to 
(1,4)-linked glucoses, as is the case for glycoamylase [41]. These results are similar to 
those previously reported when the laforin CBD was modelled based on the crystal 
structure of Bacillus circulans cyclodextrin glycosyltransferase (PDB: 2DIJ, [9]). In 
both cases, Ser25 is located at the beginning of a hairpin loop, close to the carbohydrate 
binding area (Fig. 3B). 
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 We also modelled the laforin dual specificity phosphatase domain (DSPD, 
residues 157 to 326) by comparing it with that of the human DUSP22 phosphatase 
(PDB: 1WRM; [42]) (Fig. 3C). Again, this in silico approach suggested that laforin 
DSPD folded into the characteristic fold consisting of four to five -sheets surrounded 
by -helices [43]. In this structure, the characteristic P-loop (phosphate binding-loop), 
containing the catalytic C266 residue and the WPD-loop (TPD235 in laforin) with the 
conserved Asp residue (D235) pointing towards the catalytic grove, were clearly 
observed (Fig. 3C). In this structure we were also able to map the position of residues 
S168, T187 and T194 whose mutation to Ala (Ile in the case of T194) resulted in 
impairment of interaction of laforin with different binding partners (see above). 
 Residue Ser25 is a site mutated in some Lafora disease patients. Since it is close 
to the carbohydrate binding area, we analyzed whether modifications in this residue 
could affect carbohydrate binding. With this aim we expressed GST-laforin wild type, 
S25A and S25D in yeast, as we were unable to produce the laforin-S25A mutant in 
bacteria. In addition, we expressed a human GST-VHR fusion protein as control. VHR 
(vaccinia H1-related) is a dual specificity protein phosphatase that lacks a carbohydrate 
binding domain [44]. As observed in Fig. 4A, GST-laforin wild type, S25A and S25D 
were all able to bind to amylose-sepharose. On the contrary, GST-VHR did not bind the 
amylose-sepharose, as expected. These results indicate that changing Ser25 to a small 
non-polar (Ala) or to an acidic (Asp) amino acid does not affect the capacity of laforin 
to interact with carbohydrates. 
 We next measured the in vitro phosphatase activity of the laforin mutants using 
3-O-methyl fluorescein phosphate (OMFP) as substrate (Fig. 4B). We observed that 
both mutated laforins showed a dramatic decrease in phosphatase activity, that was 
more severe in the case of laforin-S25A (20% respect to wild type). These results 
indicate that the substitution of Ser25 by either a phosphomimetic Asp residue or a non-
polar residue (Ala) appears to impair the phosphatase activity of laforin. 
 
Mutations in Ser25 affect dimerization of laforin. 
It has been described in the literature that laforin forms dimers and that mutations in the 
CBD of laforin prevent the dimerization of the protein [45]. In order to determine if 
dimerization is affected by the Ser25A/D mutants, we measured by two-hybrid analysis 
the capacity of the different forms to interact with each other. As shown in Fig. 5A, wild 
type laforin strongly interacted with itself, in agreement with the dimerization reports 
[45]. However, the laforin S25A mutant was unable to interact with itself, although it 
could form a stable interaction with wild type laforin. Alternatively, laforin S25D was 
able to interact with itself and also with wild type laforin. Western blot analyses 
confirmed that the mutated forms were expressed at similar levels as wild type.  
 Next, we sought to extend our dimerization studies from yeast into mammalian 
cells. Since the expression of the S25A form in HEK293 cells was very poor (see 
above), we tested different mammalian cell lines for their capacity to express the S25A 
mutants and found that hamster ovary (CHO) cells are able to express laforin S25A, 
although at lower levels than wild type. Extracts from these cells were subjected to non-
denaturing electrophoresis (in the absence of SDS and DTT) in order to detect the 
presence of dimeric forms of laforin. As shown in Fig. 5B, either by loading equal 
amount of total protein (left panel) or when we adjusted the amount of laforin in the 
lanes (right panel), we observed the formation of dimeric forms in wild type and S25D 
forms but an impairment in the formation of these dimers in the S25A mutant (lower 
panel shows the quantification of the proportion of dimers in the different laforin 
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forms). These results confirmed our previous yeast two-hybrid data (Fig. 5A) and 
clearly indicated that in mammalian cells, dimerization of S25A mutant is prevented. 
  
AMPK phosphorylates laforin at Ser25. 
With the identification of Ser25 as the phosphorylation site, we then set out to 
determine the kinase that phosphorylates laforin. Given that AMPK and laforin interact 
with each other [14], we searched the primary sequence of laforin for putative AMPK 
consensus motifs. It was recently determined that AMPK has preferences at six 
positions surrounding the phospho-acceptor site, with a consensus of L/M/I, K/R, 
V/S/L, x, S/T, x, x, N/E, L/M/V/I (Fig. 6A) [46]. We identified laforin Ser25 as a 
putative AMPK phosphorylation site (Fig. 6B). The residues surrounding laforin Ser25 
contain four of the six consensus residues, although no basic residues are present at the 
positions -4/-3 from the phospho-acceptor. In addition, Ser25 and the surrounding 
residues are conserved from humans to other vertebrates and even down to protists, 
which also contain AMPK (Fig. 6B). 
 To determine if AMPK could phosphorylate laforin in vitro, we incubated 
recombinant AMPK with recombinant human laforin lacking any epitope tag in the 
presence of [32-P]ATP, separated the proteins by SDS-PAGE, and visualized 
phosphorylation via autoradiography. Non-tagged laforin was phosphorylated in an 
AMPK-dependent manner (Fig. 6C), confirming our previous results that indicated 
AMPK was able to phosphorylate a GST-laforin protein fusion in vitro [14]. To identify 
the laforin residue(s) phosphorylated by AMPK, we excised bands containing laforin 
treated with and without AMPK from a Coomassie-stained gel, digested the proteins 
with trypsin, and analyzed the peptides by nano LC tandem mass spectrometry. 
Analysis of the tryptic peptides mass spectra revealed Ser25 and Thr45 as the 
phosphorylation sites (Fig. 6D & Supp. Material Fig. S1). The finding that Ser25 was a 
major phosphorylation site was in agreement with the data presented thus far. However, 
we also considered the possibility of AMPK phosphorylating laforin Thr45 and 
examined the evolutionary conservation of Thr45 and its surrounding residues. The 
residues around Thr45 of human laforin contain only two of the six residues of the 
optimal AMPK motif, and these residues, including Thr45 itself, are not conserved in 
laforin even among vertebrates (Fig. 6E). Since our two-hybrid data indicate that a 
laforin-T45A does not reduce the interaction between laforin and malin (Fig. 1A) and 
our 2DE data indicates that Ser25 is the major in vivo phosphorylation site (Fig. 2A), 
thus, we think that it is unlikely that Thr45 is a physiologically relevant AMPK target 
and instead we think it is an in vitro artefact. 
 Next, we investigated if AMPK phosphorylates laforin in tissue culture cells. We 
co-transfected HEK293 cells with FLAG-laforin and either plasmids expressing 
AMPK1 wild type (WT), AMPK1 kinase dead (KD), AMPK1 constitutively active 
(CA) or an empty vector. We grew the cells to sub-confluency, replaced the media with 
phosphate-free media containing [32P]-orthophosphate and MG132 (a proteasome 
inhibitor), incubated for 5 hours, and immunoprecipitated laforin using a denatured 
immunoprecipitation protocol [11] in order to minimize the number of non-laforin 
proteins that were recovered in the immunoprecipitates. We then separated the proteins 
in a SDS-PAGE, dried the gel, and exposed the gel to film. The autoradiograph 
demonstrates that laforin is phosphorylated in cells (Fig. 6F; third lane), and this 
phosphorylation is enhanced by the overexpression of AMPK1 (compare the first with 
the third lane). In addition, phosphorylation of laforin is improved by the 
overexpression of a constitutively active AMPK1 form (CA) (Fig. 6F; fourth lane), but 
no effect on phosphorylation of laforin is observed when overexpressing a kinase dead 
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version of AMPK (KD) (Fig. 6F, fifth lane). 
 To further prove that AMPK is involved in the in vivo phosphorylation of 
laforin, we expressed laforin in mouse embryonic fibroblasts (MEFs) from control and 
double AMPK12 KO mice and subjected cell extracts to 2DE. As shown in Fig. 7, in 
MEFs from double AMPK12 KO mice laforin migrated as a single spot, indicating 
that in the absence of AMPK, no other protein kinases are able to phosphorylate laforin. 
Cumulatively, multiple lines of evidence all confirm, first, that AMPK is able to 
phosphorylate laforin both in vitro and in vivo and, second, that this modification occurs 
at residue Ser25. 
 
 
DISCUSSION 
In this work we present evidence that laforin, a dual specificity phosphatase involved in 
Lafora disease, is a phosphoprotein in vivo and we map the residue involved in this 
modification to Ser25. In addition, we identify AMPK as the protein kinase that 
phosphorylates laforin at Ser25, both in vitro and in vivo. These results significantly 
extend our previous observation that suggested AMPK phosphorylates laforin [14] by 
identifying the site of phosphorylation. 
 Laforin-Ser25 is conserved throughout evolution. It is located in the 
carbohydrate binding domain (CBD) of laforin, close to the surface involved in sugar 
binding. We show that this residue plays critical roles in the function of laforin, since 
substitution of Ser25 by Ala, a non-polar amino acid that cannot be phosphorylated, 
results in loss of interaction of laforin-S25A with multiple known binding partners, such 
as malin, the PP1 regulatory subunit R5/PTG, and the catalytic subunit of the AMP-
activated protein kinase complex (AMPK2). Our results also indicate that the laforin-
S25A mutant exhibits decreased phosphatase activity and decreased dimerization 
capacity, although this change still allows binding of laforin-S25A to carbohydrates. 
These results may indicate that substitution of Ser25 by an Ala residue may alter the 
structure of some part of the protein, resulting in loss of interaction capabilities and loss 
of catalytic activity. The fact that wild type laforin purified from bacteria (thus, 
unphosphorylated) has full catalytic activity, suggests again that the cause of the altered 
phosphatase activity observed in the laforin-S25A mutant is a conformational change 
and not the absence of phosphorylation. This hypothesis of laforin-S25A undergoing a 
structural change would explain why the resulting protein is less stable when expressed 
in mammalian cells. Laforin-S25A would be recognized as an aberrant protein and 
would be rapidly degraded by the general proteolytic system. It has been described that 
malin ubiquitinates laforin and targets it for degradation [11]. Our data suggest that 
degradation of laforin-S25A is likely independent of malin, since no interaction 
between laforin-S25A and malin could be detected. 
 Some Lafora disease patients have mutations in Ser25, mutating Ser25 to Pro 
(S25P). Consistent with our results, a GST-laforin S25P fusion purified from bacteria 
was able to bind glycogen [47], but this laforin-S25P form did not accumulate in cell-
culture systems [48]. We therefore suggest that the presence of a non-polar amino acid 
(either proline or alanine) at residue 25 greatly affects the functionality of the mutated 
laforin in terms of loss of interaction with binding partners, decreased phosphatase 
activity, and/or reduced protein stability due to structural changes. 
In addition, we analyzed the biochemical properties of laforin-S25D, mimicking 
a constitutive phosphorylated form. We found that this mutant is able to interact with 
the assayed laforin-binding partners and it is also able to dimerize. In addition, this form 
is able to bind to carbohydrates. However, its phosphatase activity is greatly reduced. 
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Although speculative, these results suggest that phosphorylation of laforin may reduce 
its catalytic activity. 
Our alanine scanning mutagenesis data identified several Ser/Thr residues whose 
change to Ala results in increased interaction between laforin and malin. However, since 
our results indicate that laforin is mainly phosphorylated in one residue (Ser25), we 
think that the increased interaction in these other mutants is likely due to structural 
changes and not indicative of phosphorylation events. 
In conclusion, in this work we demonstrate that laforin is a phosphoprotein that 
is modified at residue Ser25 by AMPK. We have recently reported that the interaction 
between laforin and malin is enhanced by conditions activating AMPK [14]. Therefore, 
we propose that phosphorylation of Ser25 by AMPK, although it reduces the catalytic 
activity of laforin, it enhances the interaction of laforin with malin, improving the 
formation of a functional laforin-malin complex. Since both laforin and AMPK localize 
at the glycogen granule because they possess a carbohydrate binding domain, 
phosphorylation of laforin by AMPK could recruit malin to this site (Fig. 8), triggering 
the inactivation of glycogenic targets (i.e. R5/PTG, glycogen synthase, and others) and 
down-regulating glycogen synthesis. If the function of the laforin-malin complex is 
affected (either because one of the components is not functional or because the 
interaction between them is prevented), no inactivation of glycogenic targets would take 
place, resulting in increased glycogen synthesis, which eventually would lead to the 
appearance of Lafora bodies. 
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FIGURE LEGENDS 
Fig. 1: Alanine scanning mutagenesis of laforin and its effect on interaction with malin. 
A) pEG202-laforin plasmids containing the described mutations were introduced into 
CTY10-5d yeast strain in combination with plasmid pACT2-malin. Transformants were 
grown in 4% glucose containing medium until they reach exponential phase. Then, an 
aliquot of the cultures was shifted to low glucose conditions (0.05% glucose) for 3 
hours. Cells from both growth conditions were used to determine the -galactosidase 
activity, as an indication of two-hybrid interaction (see Experimental section). Results 
are the mean values of four to six different transformants, with a standard deviation of 
less than 15% in each case. B) The two-hybrid interaction between the indicated 
plasmids was measured as in (A); bars indicate standard deviation. Yeast crude extract 
(15 g) from the different transformants were analyzed by western blotting using anti-
LexA and anti-HA antibodies. Molecular size standards are in the left. C) The two-
hybrid interaction between the corresponding protein fusions was measured as above in 
cells growing in 4% glucose; bars indicate standard deviation. Yeast crude extract (15 
g) from the different transformants were analyzed by western blotting using anti-LexA 
and anti-HA antibodies. 
 
Fig. 2: Laforin is phosphorylated at residue Ser25. A) Cell extracts from HEK293 cells 
transfected with plasmids pCMVmyc-laforin (WT, S25D and T194I) were analyzed by 
2D-electrophoresis and western blotting using anti-myc monoclonal antibodies. Cell 
extracts were also treated with -phosphatase as described in Experimental section. The 
calculated pI for each spot is indicated. Molecular size standards are indicated in the 
right. B) Cell extracts from HEK293 cells co-transfected with plasmids pCMVmyc-
laforin (WT, S25A and S25D) and pEGFP-N1 (expressing GFP), were prepared for 
immunodetection as described in Experimental section. In this case, lysis buffer 
contained 0.5% TritonX100 instead of 0.5% nonidet P40. Extracts were centrifuged at 
13,000 rpm for 10 min at 4ºC to separate soluble from pellet fractions. These fractions 
were treated with SDS-PAGE sample buffer and analyzed by western blotting using 
anti-myc and anti-GFP antibodies. C) HEK293 cells co-transfected with plasmids 
pCMVmyc-laforin (WT, S25A and S25D) were treated or not with 10 M MG132 (a 
proteasome inhibitor) for 8 hours. Then, crude extracts were obtained and analyzed by 
western blotting using anti-myc and anti-tubulin (loading control). 
 
Fig. 3: Structure models of laforin CBD and DSPD domains. A) Diagram of the 
position of the CBD and DSPD domain in the primary structure of human laforin. The 
positions of residues described in this work are also indicated. B) Laforin CBD domain 
(residues 1-116) was in silico modelled, as described in Experimental section, using the 
crystal structure of Geobacillus stearothermophilus cyclodextrin glycosyltransferase 
(PDB: 1CYG) as a template. The positions of the Trp residues involved in carbohydrate 
binding (W32, W85 and W99) are indicated in green and the position of residue Ser25 
is marked in red. -cyclodextrin is coloured in blue. The N-terminus is also indicated. 
C) The laforin dual specificity phosphatase domain (residues 157-326) was in silico 
modelled, as described in Experimental procedures, using the crystal structure of human 
DUSP22 (PDB: 1WRM) as a template. The position of the characteristic P-loop, 
containing the catalytic C266 residue (in red), and the WPD-loop, containing the 
conserved D235 (in yellow), is indicated. The positions of other residues described in 
this study (S168, T187 and T194; in green) and the C-terminus are also indicated. 
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Fig. 4: Effect of laforin-S25A/D mutations on carbohydrate binding capacity and 
phosphatase activity. A) Laforin-S25A and S25D mutations do not affect carbohydrate 
binding capacity of laforin. Yeast crude extracts (CE) containing GST-laforin (WT, 
S25A and S25D) and GST-VHR fusion proteins were passed through columns 
containing amylose-sepharose. Flow-through (FT) was collected and columns were 
washed twice with 5 ml of extraction buffer, collecting the last wash (W). Bound 
proteins (B) were eluted with 50 l of SDS-PAGE sample buffer. Collected samples 
were analysed by SDS-PAGE and western blotting using anti-GST antibodies. A similar 
volume (30 l) of CE, FT and the corresponding W was analyzed. B) Effect of S25A 
and S25D mutations on phosphatase activity of laforin. Phosphatase activity was 
measured on GST-laforin WT, S25A and S25D proteins purified from yeast. 
Phosphatase activity was referred to the activity found in the corresponding wild type 
laforin. Statistical significance was considered at ** p<0.01 (n:3).  
 
Fig. 5: Effect of laforin-S25A/D mutations on dimerization capability. A) CTY10.5d 
yeast cells transformed with the indicated plasmids were used to measure the two-
hybrid interaction between the indicated proteins, as in legend of Fig. 1. Results are the 
mean values of four to six different transformants; bars indicate standard deviation. 
Yeast crude extract (15 g) from the different transformants were analyzed by western 
blotting using anti-LexA and anti-HA antibodies. B) Crude extracts from hamster ovary 
(CHO) cells transfected with plasmids pCMVmyc-laforin (WT, S25D and S25A) were 
analyzed by non-denaturing electrophoresis and western blotting using anti-myc 
monoclonal antibodies. Different amounts of the extracts were loaded as indicated. CE, 
crude extracts. Lower panel shows the quantification of the proportion of dimers in cells 
expressing the different laforin forms. Values are means of three independent 
experiments (bars indicate standard deviation, *p<0.05). 
 
Fig. 6: AMPK phosphorylates laforin at Ser25. A) Optimal AMPK motifs; modified 
from [46]. B) Evolutionary conservation of a putative AMPK site at laforin-Ser25. C) In 
vitro phosphorylation of recombinant non-tagged laforin by recombinant AMPK. D) 
MS/MS identification of the phosphorylation site Ser25 in the laforin tryptic peptide 
PELLVVGSRPELGR. Individual fragment ions are labelled [y-ions: blue; b-ions: 
green; –P denotes the neutral loss of H3PO4 (-98 Da)]. E) Evolutionary conservation of 
laforin-Thr45. F) HEK293 cells were transfected with FLAG-laforin and AMPK1 wild 
type, -kinase dead (KD), -constitutively active (CA) forms or empty vector, as 
indicated. Cells were incubated in [32P]-orthophosphate and MG132 as described in 
Experimental section. Laforin was immunoprecipitated, proteins separated on a SDS-
PAGE gel, which was dried and exposed onto film. Actin levels were used as loading 
control of the amount of proteins in the crude extracts. 
 
Fig. 7: Laforin is not phosphorylated in the absence of AMPK. Mouse embryonic 
fibroblasts (MEFs) from control and double AMPK12 KO mice were transfected 
with plasmid pCMVmyc-laforin. Cell extracts were analyzed by 2D-electrophoresis and 
western blotting using anti-myc monoclonal antibodies, as in legend of Fig. 2. The 
calculated pI for each spot is indicated. Molecular size standards are indicated in the 
right.  
 
Fig. 8: Proposed model of the action of the laforin-malin complex in the regulation of 
glycogen synthesis. Interaction between laforin and malin is enhanced by 
phosphorylation of laforin at Ser25 by AMPK (1). A more stable laforin-malin complex 
 20
results (indicated by the red arrow, 2), resulting in increased ubiquitination of specific 
substrates, e.g. R5/PTG, glycogen synthase (GS), and glycogen debranching enzyme 
(AGL/GDE), leading to down-regulation of glycogen synthesis. 
 
 
